1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies
insider
insider
Articles 

Cormorant Asset Management, LLC Buys InflaRx NV, ChemoCentryx Inc, Galapagos NV, Sells Tesaro Inc, Dicerna Pharmaceuticals Inc, Mirati Therapeutics Inc

Boston, MA, based Investment company Cormorant Asset Management, LLC buys InflaRx NV, ChemoCentryx Inc, Galapagos NV, Ascendis Pharma A/S, CRISPR Therapeutics AG, Autolus Therapeutics PLC, Sarepta Therapeutics Inc, Allakos Inc, Biohaven Pharmaceutical Holding Co, Atara Biotherapeutics Inc, Myovant Sciences, Kura Oncology Inc, Gossamer Bio Inc, Precision BioSciences Inc, Y-mAbs Therapeutics Inc, Tricida Inc, Blueprint Medicines Corp, Rubius Therapeutics Inc, Eidos Therapeutics Inc, sells Tesaro Inc, Dicerna Pharmaceuticals Inc, Mirati Therapeutics Inc, Theravance Biopharma Inc, G1 Therapeutics Inc, Avrobio Inc, argenx SE, Kiniksa Pharmaceuticals, Incyte Corp, Apellis Pharmaceuticals Inc, Solid Biosciences Inc, Zai Lab, Neurocrine Biosciences Inc, Sage Therapeutics Inc, Replimune Group Inc, CytomX Therapeutics Inc, ContraFect Corp, MeiraGTx Holdings PLC, Sangamo Therapeutics Inc, Quanterix Corp, Arqule Inc during the 3-months ended 2019Q1, according to the most recent filings of the investment company, Cormorant Asset Management, LLC. As of 2019Q1, Cormorant Asset Management, LLC owns 57 stocks with a total value of $1.4 billion. These are the details of the buys and sells.

For the details of Cormorant Asset Management, LLC's stock buys and sells, go to https://www.gurufocus.com/guru/cormorant+asset+management%2C+llc/current-portfolio/portfolio

These are the top 5 holdings of Cormorant Asset Management, LLC
  1. InflaRx NV (IFRX) - 2,590,000 shares, 6.85% of the total portfolio. Shares added by 75.58%
  2. SPDR Series Trust S&P Biotech (XBI) - 925,000 shares, 5.86% of the total portfolio.
  3. Mirati Therapeutics Inc (MRTX) - 1,075,000 shares, 5.52% of the total portfolio. Shares reduced by 38.63%
  4. Ascendis Pharma A/S (ASND) - 600,000 shares, 4.94% of the total portfolio. Shares added by 77.28%
  5. Apellis Pharmaceuticals Inc (APLS) - 3,600,000 shares, 4.91% of the total portfolio. Shares reduced by 20.04%
New Purchase: ChemoCentryx Inc (CCXI)

Cormorant Asset Management, LLC initiated holding in ChemoCentryx Inc. The purchase prices were between $10.01 and $13.89, with an estimated average price of $11.44. The stock is now traded at around $12.35. The impact to a portfolio due to this purchase was 2.46%. The holding were 2,525,900 shares as of .

New Purchase: Galapagos NV (GLPG)

Cormorant Asset Management, LLC initiated holding in Galapagos NV. The purchase prices were between $89.61 and $117.78, with an estimated average price of $100.78. The stock is now traded at around $114.30. The impact to a portfolio due to this purchase was 2.45%. The holding were 300,000 shares as of .

New Purchase: Autolus Therapeutics PLC (AUTL)

Cormorant Asset Management, LLC initiated holding in Autolus Therapeutics PLC. The purchase prices were between $24.38 and $34.71, with an estimated average price of $28.56. The stock is now traded at around $23.90. The impact to a portfolio due to this purchase was 1.87%. The holding were 850,000 shares as of .

New Purchase: Atara Biotherapeutics Inc (ATRA)

Cormorant Asset Management, LLC initiated holding in Atara Biotherapeutics Inc. The purchase prices were between $28.4 and $41.74, with an estimated average price of $37.18. The stock is now traded at around $24.85. The impact to a portfolio due to this purchase was 1.53%. The holding were 550,000 shares as of .

New Purchase: Myovant Sciences Ltd (MYOV)

Cormorant Asset Management, LLC initiated holding in Myovant Sciences Ltd. The purchase prices were between $16.41 and $24.45, with an estimated average price of $20.37. The stock is now traded at around $13.51. The impact to a portfolio due to this purchase was 1.09%. The holding were 650,000 shares as of .

New Purchase: Gossamer Bio Inc (GOSS)

Cormorant Asset Management, LLC initiated holding in Gossamer Bio Inc. The purchase prices were between $17.58 and $23.97, with an estimated average price of $20.81. The stock is now traded at around $20.49. The impact to a portfolio due to this purchase was 0.99%. The holding were 653,129 shares as of .

Added: InflaRx NV (IFRX)

Cormorant Asset Management, LLC added to a holding in InflaRx NV by 75.58%. The purchase prices were between $31.16 and $48.62, with an estimated average price of $37.15. The stock is now traded at around $41.60. The impact to a portfolio due to this purchase was 2.95%. The holding were 2,590,000 shares as of .

Added: Ascendis Pharma A/S (ASND)

Cormorant Asset Management, LLC added to a holding in Ascendis Pharma A/S by 77.28%. The purchase prices were between $62.15 and $129.99, with an estimated average price of $86.75. The stock is now traded at around $121.81. The impact to a portfolio due to this purchase was 2.15%. The holding were 600,000 shares as of .

Added: CRISPR Therapeutics AG (CRSP)

Cormorant Asset Management, LLC added to a holding in CRISPR Therapeutics AG by 800.00%. The purchase prices were between $28.02 and $40.87, with an estimated average price of $34.47. The stock is now traded at around $38.67. The impact to a portfolio due to this purchase was 2%. The holding were 900,000 shares as of .

Added: Sarepta Therapeutics Inc (SRPT)

Cormorant Asset Management, LLC added to a holding in Sarepta Therapeutics Inc by 233.33%. The purchase prices were between $106.67 and $151.68, with an estimated average price of $128.32. The stock is now traded at around $119.19. The impact to a portfolio due to this purchase was 1.75%. The holding were 300,000 shares as of .

Added: Allakos Inc (ALLK)

Cormorant Asset Management, LLC added to a holding in Allakos Inc by 400.00%. The purchase prices were between $33.79 and $52.27, with an estimated average price of $40.54. The stock is now traded at around $41.65. The impact to a portfolio due to this purchase was 1.7%. The holding were 750,000 shares as of .

Added: Biohaven Pharmaceutical Holding Co Ltd (BHVN)

Cormorant Asset Management, LLC added to a holding in Biohaven Pharmaceutical Holding Co Ltd by 69.23%. The purchase prices were between $34.52 and $53.29, with an estimated average price of $43.04. The stock is now traded at around $61.78. The impact to a portfolio due to this purchase was 1.62%. The holding were 1,100,000 shares as of .

Sold Out: Tesaro Inc (TSRO)

Cormorant Asset Management, LLC sold out a holding in Tesaro Inc. The sale prices were between $74.02 and $74.96, with an estimated average price of $74.7.

Sold Out: Dicerna Pharmaceuticals Inc (DRNA)

Cormorant Asset Management, LLC sold out a holding in Dicerna Pharmaceuticals Inc. The sale prices were between $9.74 and $14.65, with an estimated average price of $11.47.

Sold Out: Theravance Biopharma Inc (TBPH)

Cormorant Asset Management, LLC sold out a holding in Theravance Biopharma Inc. The sale prices were between $22.57 and $28.15, with an estimated average price of $25.42.

Sold Out: G1 Therapeutics Inc (GTHX)

Cormorant Asset Management, LLC sold out a holding in G1 Therapeutics Inc. The sale prices were between $14.4 and $21.45, with an estimated average price of $19.02.

Sold Out: Replimune Group Inc (REPL)

Cormorant Asset Management, LLC sold out a holding in Replimune Group Inc. The sale prices were between $10 and $16.24, with an estimated average price of $12.42.

Sold Out: ContraFect Corp (CFRX)

Cormorant Asset Management, LLC sold out a holding in ContraFect Corp. The sale prices were between $0.36 and $1.94, with an estimated average price of $0.56.

Reduced: Mirati Therapeutics Inc (MRTX)

Cormorant Asset Management, LLC reduced to a holding in Mirati Therapeutics Inc by 38.63%. The sale prices were between $42.42 and $78.95, with an estimated average price of $67.65. The stock is now traded at around $63.50. The impact to a portfolio due to this sale was -2.38%. Cormorant Asset Management, LLC still held 1,075,000 shares as of .

Reduced: Avrobio Inc (AVRO)

Cormorant Asset Management, LLC reduced to a holding in Avrobio Inc by 77.91%. The sale prices were between $12.46 and $22.05, with an estimated average price of $15.23. The stock is now traded at around $18.40. The impact to a portfolio due to this sale was -1.46%. Cormorant Asset Management, LLC still held 300,000 shares as of .



Here is the complete portfolio of Cormorant Asset Management, LLC. Also check out:

1. Cormorant Asset Management, LLC's Undervalued Stocks
2. Cormorant Asset Management, LLC's Top Growth Companies, and
3. Cormorant Asset Management, LLC's High Yield stocks
4. Stocks that Cormorant Asset Management, LLC keeps buying

Rating: 0.0/5 (0 votes)

Comments

Please leave your comment:


Performances of the stocks mentioned by insider


User Generated Screeners


pjmason14Momentum
pascal.van.garsseHigh FCF-M2
kosalmmuse6
kosalmmuseBest one1
DBrizanall 2019Feb26
kosalmmuseBest one
DBrizanall 2019Feb25
kosalmmuseNice
kosalmmusehan
MsDale*52-Week Low
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK